HemoBioTech announces filing of patent application for blood loss treatment.

BIOTECH Patent News, May, 2006

HemoBioTech, Inc. (Dallas, TX) said that Texas Tech University filed a patent application for induction of erythropoiesis (red blood cell production) by HemoTech, a novel chemically modified hemoglobin. HemoBioTech has a worldwide exclusive license to HemoTech, which is being developed as a blood substitute.

"We are very excited about the erythropoietic property of HemoTech," said Dr. Arthur P. Bollon, Chairman and CEO of HemoBioTech. "There is a strong interest in new agents which increase the level of red blood cells in patients. The development of a blood substitute that not only carries oxygen, but also increases the level of red blood cells, could have broad applications in medicine, especially trauma, elective surgery, acute anemia, cancer and heart...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.